Literature DB >> 2840310

Pharmacodynamics of the antiprogesterone RU486 in women after oral administration.

J H Liu1, V G Garzo, S S Yen.   

Abstract

The pharmacokinetic characteristics of RU486 and its acute effects on anterior pituitary hormone secretion after oral administration were examined in six normal women. Serum RU486 concentrations were determined by a radioimmunoassay. The absorption of RU486 was rapid with peak serum levels reached approximately 90 minutes after a single oral dose (4 mg/kg). The disappearance of RU486 and its metabolites conformed to a noncompartmental model with a mean apparent half-life of 53.7 +/- 6.9 hours. The mean apparent volume of distribution and clearance rate were 1.47 +/- 0.25 l/kg and 1.04 +/- 0.09 1/hour, respectively. In comparison with a control group of normal women (n = 9), there were significant elevations in transverse mean cortisol levels in the RU486 group (P less than 0.01). However, mean adrenocorticotropic hormone (ACTH) levels and the diurnal pattern of ACTH and cortisol secretion were not changed. RU486 induced a mild prolactin (PRL) elevation (P less than 0.01), whereas thyroid-stimulating hormone (TSH) and luteinizing hormone (LH) levels were not altered. In view of the relatively slow clearance rate for RU486 and its metabolites, our findings suggest that the pharmacologic action of RU486 is prolonged after a single oral dose.

Entities:  

Keywords:  Biology; Data Analysis; Drugs--pharmacodynamics; Endocrine System; Examinations And Diagnoses; Family Planning; Gonadotropins; Gonadotropins, Pituitary; Hormones; Laboratory Examinations And Diagnoses; Menstrual Cycle; Menstruation; Physiology; Pituitary Hormones; Prolactin--analysis; Reproduction; Reproductive Control Agents; Research Methodology; Treatment

Mesh:

Substances:

Year:  1988        PMID: 2840310     DOI: 10.1016/s0015-0282(16)60067-5

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  6 in total

1.  Clinical pharmacokinetics of mifepristone.

Authors:  O Heikinheimo
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

2.  Phase I/II trial of the anti-HIV activity of mifepristone in HIV-infected subjects ACTG 5200.

Authors:  Michael F Para; Jeff Schouten; Susan L Rosenkranz; Song Yu; David Weiner; Pablo Tebas; C Jo White; Dominic Reeds; Juan Lertora; Kristine B Patterson; Eric S Daar; Winston Cavert; Barbara Brizz
Journal:  J Acquir Immune Defic Syndr       Date:  2010-04-01       Impact factor: 3.731

3.  Estradiol and progesterone-induced slowing of gonadotropin-releasing hormone pulse frequency is not reversed by subsequent administration of mifepristone.

Authors:  Christopher R McCartney; Susan K Blank; John C Marshall
Journal:  Endocrine       Date:  2009-07-16       Impact factor: 3.633

4.  In vivo exposure to high or low cortisol has biphasic effects on inflammatory response pathways of human monocytes.

Authors:  Mark P Yeager; Patricia A Pioli; Kathleen Wardwell; Michael L Beach; Peter Martel; Hong K Lee; Athos J Rassias; Paul M Guyre
Journal:  Anesth Analg       Date:  2008-11       Impact factor: 5.108

5.  A method for overcoming plasma protein inhibition of tyrosine kinase inhibitors.

Authors:  David J Young; Bao Nguyen; Li Li; Tomoyasu Higashimoto; Mark J Levis; Jun O Liu; Donald Small
Journal:  Blood Cancer Discov       Date:  2021-07-02

Review 6.  Systemic therapy of Cushing's syndrome.

Authors:  Niels Eckstein; Bodo Haas; Moritz David Sebastian Hass; Vladlena Pfeifer
Journal:  Orphanet J Rare Dis       Date:  2014-08-05       Impact factor: 4.123

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.